Dalbavancin For The Treatment of Gram Positive Osteoarticular Infections
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
Because of its prolonged terminal half-life, dalbavancin is an extremely attractive option in
treating Gram-positive infections caused by S. aureus including MRSA, and streptococcal
species. Systemic bacterial infections due to Staphylococci such as osteomyelitis and septic
arthritis, are conditions which require prolonged IV therapy, typically for at least 3-6
weeks, though sometimes more. Due to dalbavancin's prolonged terminal half-life, it may offer
the opportunity to substantially reduce costs and morbidity in native joint and prosthetic
joint infections with one infusion every fourteen days until completion of therapy.